Breakthrough vaccine could eradicate breast cancer, shows 75% immune response in trial

The most common cancer in women — and one of the deadliest — may have finally met its match.Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up phase one of its clinical trial this week, with more than 75% of women showing a strong immune response, as measured by antibodies on their white blood cells.

The vaccine is aimed at both preventing and treating breast cancer — which affects one in eight women.“It’s very exciting,” said Dr.Amit Kumar, CEO of Anixa Biosciences, which is designing the vaccine along with the Cleveland Clinic.During the trial’s first phase, researchers gave the vaccine to 35 women, most of them with triple negative breast cancer — the most lethal form.

It’s the type that famously led Angelina Jolie to undergo a preventative double mastectomy at 37, after finding out she had the genetic mutation for the disease.The women had their blood drawn periodically to measure the level of antibody production on their T and B cells – two types of white blood cells – against alpha-lactalbumin, the molecule targeted by the vaccine.Researchers said the only side effect observed was irritation at the injection site.“It’s a very new mechanism and we think that if this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we’ve done for polio and various other infectious diseases,” Kumar told The Post.Phase two, set to begin next year, will test the vaccine on a larger group, and for other types of breast cancer.“Cancer vaccines have been very, very difficult to develop,” he added.“There’s never been a successful true cancer vaccine.”Unlike vaccines for infectious diseases, which target organisms foreign to the body like viruses, cancer is a different ballgame since it grows out of a person’s own cells.“The cancer cells arise out of your own healthy cells … so the immune system is not able to see very distinctly th...